このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

InfuSystem Holdings 将来の成長

Future 基準チェック /46

InfuSystem Holdingsは、129.1%と9%でそれぞれ年率129.1%で利益と収益が成長すると予測される一方、EPSはgrowで128.5%年率。

主要情報

129.1%

収益成長率

128.5%

EPS成長率

Healthcare 収益成長	17.1%
収益成長率	9.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	06 Jun 2024

今後の成長に関する最新情報

Recent updates

If You Like EPS Growth Then Check Out InfuSystem Holdings (NYSEMKT:INFU) Before It's Too Late

Feb 19

業績と収益の成長予測

NYSEAM:INFU - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	163	N/A	23	N/A	1
12/31/2025	148	8	14	27	3
12/31/2024	135	2	8	18	3
3/31/2024	127	0	3	12	N/A
12/31/2023	126	1	0	11	N/A
9/30/2023	123	1	-2	11	N/A
6/30/2023	118	1	-5	10	N/A
3/31/2023	114	0	-3	13	N/A
12/31/2022	110	0	2	18	N/A
9/30/2022	108	0	-1	17	N/A
6/30/2022	107	-1	1	19	N/A
3/31/2022	104	0	2	20	N/A
12/31/2021	102	1	2	18	N/A
9/30/2021	100	12	8	22	N/A
6/30/2021	99	15	12	25	N/A
3/31/2021	100	18	8	22	N/A
12/31/2020	97	17	3	20	N/A
9/30/2020	94	7	-2	17	N/A
6/30/2020	90	6	-10	14	N/A
3/31/2020	84	2	-10	13	N/A
12/31/2019	81	1	-9	14	N/A
9/30/2019	77	0	-7	13	N/A
6/30/2019	72	-1	-3	11	N/A
3/31/2019	69	-2	1	12	N/A
12/31/2018	67	-1	3	11	N/A
9/30/2018	67	-19	7	12	N/A
6/30/2018	67	-18	8	11	N/A
3/31/2018	66	-19	7	10	N/A
12/31/2017	65	-21	N/A	8	N/A
9/30/2017	63	-3	N/A	8	N/A
6/30/2017	63	-3	N/A	7	N/A
3/31/2017	64	-2	N/A	6	N/A
12/31/2016	65	0	N/A	8	N/A
9/30/2016	67	2	N/A	5	N/A
6/30/2016	68	3	N/A	5	N/A
3/31/2016	66	3	N/A	9	N/A
12/31/2015	65	3	N/A	7	N/A
9/30/2015	63	2	N/A	8	N/A
6/30/2015	62	2	N/A	9	N/A
3/31/2015	61	2	N/A	6	N/A
12/31/2014	61	3	N/A	7	N/A
9/30/2014	61	3	N/A	7	N/A
6/30/2014	59	3	N/A	7	N/A
3/31/2014	58	2	N/A	5	N/A
12/31/2013	56	2	N/A	7	N/A
9/30/2013	54	1	N/A	4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: INFUの予測収益成長率 (年間129.1% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: INFUの収益 ( 129.1% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: INFUの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: INFUの収益 ( 9% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: INFUの収益 ( 9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: INFUの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

InfuSystem Holdings 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024

InfuSystem Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023

Consensus EPS estimates fall by 25%, revenue upgraded

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 15%

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Recent updates

CEO & Director exercised options and sold US$142k worth of stock

Less than half of directors are independent

InfuSystem Holdings, Inc. (NYSEAM:INFU) announces an Equity Buyback for $20 million worth of its shares.

InfuSystem Holdings, Inc. Approves Directorate Elections

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024

InfuSystem Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

InfuSystem Holdings, Inc., Annual General Meeting, May 16, 2024

InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K

InfuSystem Holdings, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

InfuSystem Holdings, Inc. Announces Resignation of R. Rimmy Malhotra as Member of the Board

InfuSystem Holdings, Inc. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

InfuSystem Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023

InfuSystem Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CEO & Director exercised options and sold US$870k worth of stock

Consensus EPS estimates fall by 25%, revenue upgraded

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

InfuSystem Holdings, Inc. to Report Q2, 2023 Results on Aug 03, 2023

President exercised options and sold US$79k worth of stock

Independent Director notifies of intention to sell stock

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 15%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Executive VP & CFO exercised options and sold US$92k worth of stock

Full year 2022 earnings released: EPS: US$0.001 (vs US$0.069 in FY 2021)

Independent Director exercised options and sold US$101k worth of stock

Independent Director exercised options and sold US$114k worth of stock

Independent Director exercised options and sold US$114k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2022

InfuSystem Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

InfuSystem Holdings, Inc. Announces the Appointment of R. Rimmy Malhotra to Board of Directors, Effective September 20, 2022

Independent Director exercised options and sold US$70k worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$56k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

InfuSystem Holdings Inc. Revises Earnings Guidance for the Year 2022

InfuSystem Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

InfuSystem Holdings, Inc.(NYSEAM:INFU) dropped from Russell 2000 Dynamic Index

Independent Director exercised options and sold US$206k worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$119k worth of stock

Independent Director exercised options and sold US$66k worth of stock

InfuSystem Holdings Inc. Approves Appointment of Ralph Boyd to the Company's Board

Consensus EPS estimates fall by 38%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

InfuSystem Holdings Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$21.67

InfuSystem Holdings Inc., Annual General Meeting, May 17, 2022

Director exercised options and sold US$175k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 49%

Independent Director recently bought US$107k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

InfuSystem Holdings Inc. to Report Q4, 2021 Results on Feb 10, 2022

CEO & Director notifies of intention to sell stock

Insider exercised options and sold US$101k worth of stock

Third quarter 2021 earnings released: US$0.022 loss per share (vs US$0.15 profit in 3Q 2020)

Independent Director exercised options to buy US$399k worth of stock.

Investor sentiment improved over the past week

Consensus EPS estimates fall to US$0.19

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.21 in 2Q 2020)

InfuSystem Holdings Inc. Revises Earnings Guidance for the Full Year 2021

Investor sentiment deteriorated over the past week